Ascensia announces coverage expansion for CGM system
By HME News Staff
Updated 10:08 AM CST, Mon February 12, 2024
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of local coverage determinations that provide access to implantable CGM for basal-only patients. Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple inulin administrations per day. Coverage has also been updated to cover non-insulin users who have a history of problematic hypoglycemia. “We welcome this policy change and look forward to bringing this differentiated CGM option to millions of more Americans through Medicare,” said Rudy Thoms, vice president, CGM Commercial U.S., for Ascensia. “Eversense E3 is a truly unique technology and optionality is key in diabetes care, where what works for one person does not always work for all. In particular, our Medicare users love that this twice-yearly CGM offers them unparalleled reliability and flexibility, without the burden of regular self-insertions and the constant reordering of supplies. It is important that people with diabetes have the same access to the benefits of a fully implantable, long-term CHM, as they do traditional CGMs and so we are thrilled to see this expansion.” Noridian, Palmetto and National Government Services are the first three MACs to publish final local coverage determinations. The earliest MAC expansion becomes effective Feb. 25, 2024.
Comments